Ibogaine for Traumatic Brain Injury: What Stanford Found

Psiconáutica Editorial Team

Ibogaine, an alkaloid from the African plant Tabernanthe iboga, has drawn decades of interest as a potential aid for addiction. A recent study from Stanford University put it to the test in a different but related field: military veterans with traumatic brain injury (TBI) and the psychiatric sequelae that often accompany it. The striking results invite both cautious optimism and careful scrutiny.

The study

The work was published in Nature Medicine (Volume 30, pages 373–381, 2024), authored by Cherian, Keynan, Anker, and colleagues, with Nolan R. Williams as the principal investigator at the Stanford Brain Stimulation Lab. It is an observational, prospective, open-label study: there was no placebo group or random assignment. Thirty men, all veterans of U.S. special operations forces with predominantly mild TBI and a history of PTSD, depression, and functional impairment, participated. All traveled to a clinic outside the United States, where they received a single dose of ibogaine following the protocol dubbed MISTIC (Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS), which administers magnesium as a complement to reduce the alkaloid’s cardiac risk.

What was found

Measurements were taken before treatment, immediately after, and at a one-month follow-up. The improvements were statistically large. In daily functioning (WHODAS-2.0 scale), the effect size went from moderate immediately after treatment (d = 0.74) to very large at one month (d = 2.20). At the one-month follow-up, PTSD scores (CAPS-5) showed an effect size of d = 2.54; depression (MADRS) was d = 2.80; and anxiety (HAM-A) was d = 2.13. All these changes were statistically significant (p < 0.001). The authors also reported reductions in suicidal ideation. Regarding safety, no serious cardiac adverse effects or major events were recorded during the study—a relevant point, as ibogaine has historically been associated with potentially fatal arrhythmias, hence the co-administration of magnesium.

What it means (and what it doesn’t)

These numbers should be read with a grain of salt. On one hand, effect sizes of this magnitude are unusually high in mental health, and the fact that they appear after a single session in a difficult-to-treat patient profile is a legitimate reason for scientific interest. On the other hand, the design imposes serious limitations that the authors themselves acknowledge. There was no control or placebo group, so it cannot be ruled out that part of the improvement is due to expectation, the experience itself, the intensive therapeutic support surrounding the intervention, or the motivation of those who sign up for such a study. The sample is small (30 people), homogeneous (men, elite veterans), and self-selected, which significantly limits the extent to which these results can be extrapolated to other individuals or the general population. Furthermore, the follow-up was short: one month says nothing about whether the benefits are maintained long-term.

There is also an important nuance regarding the scope. Although ibogaine has been researched primarily as an aid for opioid and other substance dependencies, this study did not measure consumption or addiction: its focus was the sequelae of brain injury and associated psychiatric symptoms. Linking the two fields is a reasonable hypothesis, but they are distinct objects of study.

Finally, there is the practical and legal reality, which should be stated as a fact, not a sermon. Ibogaine is not an innocuous substance: its cardiac toxicity is real and has caused deaths in unsupervised contexts, which is why everything described here took place under close medical supervision, with prior cardiac screening and protective magnesium. In many countries, including Spain and the United States, its legal status restricts its use, which is why the trial was conducted outside U.S. territory. None of this makes it an available or recommended treatment for self-administration. The honest approach is to state both things at once: it is a hopeful line of research that deserves larger, randomized controlled trials, and at the same time, it is a high-risk compound that should not be used outside a rigorous clinical environment today.

Source

• Cherian KN, Keynan JN, Anker L, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 2024; 30(2):373-381. DOI: 10.1038/s41591-023-02705-w

Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.